Impact of P2Y₁₂ Inhibitor Pretreatment on Clinical Outcomes in ST‐Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study
Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1100-1111
DOI: 10.1002/ccd.70449 ↗At a glance
Multizentrische Studie in Catheterization and Cardiovascular Interventions, published online on 2025-12-29. Written by Abdul Qadeer and 14 co-authors. Institution: Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas, USA. Major MEDLINE topics: Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Cited 2 times so far (Crossref); 17 references. Funded by: UTMB Institute for Translational Sciences, National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).
Abstract (original language)
Background
The benefit of P2Y₁₂ inhibitor pretreatment before primary percutaneous coronary intervention (PCI) in ST‐segment elevation myocardial infarction (STEMI) remains uncertain.
Aims
This study examined the association between pretreatment and short‐ and long‐term cardiovascular outcomes.
Methods
In this retrospective cohort study, adults (≥ 18 years) hospitalized for STEMI and undergoing PCI were identified from the TriNetX US Collaborative Network (January 2010 to December 2024). Patients receiving P2Y₁₂ inhibitors before PCI ( n = 72,913) were matched 1:1 by propensity score to those without pretreatment ( n = 66,450), yielding 21,689 patients per group. Primary endpoints at 1 month and 1 year included all‐cause mortality, major adverse cardiovascular events (MACE), stent thrombosis, and stent restenosis. Multivariable Cox regression provided adjusted hazard ratios (HRs) with 95% confidence intervals (CIs).
Results
After matching, baseline characteristics were balanced (all standardized mean differences < 0.10). At 1 month, pretreatment was associated with higher all‐cause mortality (4.5% vs. 4.0%; RR 1.13; p = 0.007), MACE (8.7% vs. 7.5%; RR 1.16; p < 0.001), stent thrombosis (1.9% vs. 0.8%; RR 2.39; p < 0.001), and stent restenosis (5.3% vs. 4.0%; RR 1.32; p < 0.001). These differences persisted at 1 year (mortality 10.2% vs. 9.0%; RR 1.14; p < 0.001; MACE 18.9% vs. 18.2%; RR 1.04; p < 0.001; thrombosis 2.4% vs. 1.1%; RR 2.26; p < 0.001; restenosis 11.0% vs. 9.6%; RR 1.14; p < 0.001). Secondary endpoints showed no differences in major bleeding or cardiac arrest, while ischemic stroke was lower at 1 month and MI recurrence was reduced at 6 months and 1 year. In Cox models, pretreatment predicted higher 1‐year hazards for mortality, MACE, and restenosis, and a threefold increase in 1‐month stent thrombosis.
Conclusion
In this retrospective, non‐randomized analysis of administrative data from the TriNetX database, P2Y₁₂ inhibitor pretreatment before PCI in STEMI was linked to modestly increased 1‐year risks of mortality, MACE, and restenosis, and markedly higher 1‐month stent thrombosis, highlighting the need for prospective trials to optimize antiplatelet strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
- King Edward Medical University, Lahore, Pakistan.
- Dow International Medical College, Karachi, Pakistan.
- Guntur Medical College, Guntur, India.
- Alexandria Faculty of Medicine, Alexandria, Egypt.
- Charleston Area Medical Center, Charleston, West Virginia, USA.
ORCID profiles: Qais Bin Abdul Ghaffar, Muhammad Umer Ishaq, Mirza Muhammad Hadeed Khawar, Malik Sohail Riaz
Funding
- UTMB Institute for Translational Sciences
- National Center for Advancing Translational Sciences at the National Institutes of Health (NIH)
Cite
APA
Qadeer, A., Khawar, M., Abdul Ghaffar, Q. B., Jain, S., Fouad, M., Kanwal, K., Muhammad, A., Iqbal Ghuman, S., Bintay Khalid, M., Gohar, N., Umer Ishaq, M., Chaudhary, M., Hadeed Khawar, M. M., Riaz, M. S., & Anil, K. C. (2026). Impact of P2Y₁₂ Inhibitor Pretreatment on Clinical Outcomes in ST‐Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study. Catheterization and Cardiovascular Interventions, 107(4), 1100-1111. https://doi.org/10.1002/ccd.70449
Vancouver
Qadeer A, Khawar M, Abdul Ghaffar QB, Jain S, Fouad M, Kanwal K, et al. Impact of P2Y₁₂ Inhibitor Pretreatment on Clinical Outcomes in ST‐Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study. Catheterization and Cardiovascular Interventions. 2026;107(4):1100-1111. doi:10.1002/ccd.70449
BibTeX
@article{Qadeer2026,
author = {Qadeer, Abdul and Khawar, Muneeb and Abdul Ghaffar, Qais Bin and Jain, Samiksha and Fouad, Michele and Kanwal, Kainat and Muhammad, Awon and Iqbal Ghuman, Shameer and Bintay Khalid, Marwah and Gohar, Najam and Umer Ishaq, Muhammad and Chaudhary, Mueed and Hadeed Khawar, Mirza Muhammad and Riaz, Malik Sohail and Anil, K C},
title = {Impact of P2Y₁₂ Inhibitor Pretreatment on Clinical Outcomes in ST‐Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Cohort Study},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {4},
pages = {1100--1111},
doi = {10.1002/ccd.70449}
}
EUVIMED